Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | PGK1 | P00558 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3970707 | 0.85 | PDGFRB (0.53) | CYP1A2PDE10ANQO2KDM4EALDH1A1 | |
| SCHEMBL3968464 | 0.84 | PGK1 (0.46) | PGK1GSK3BMAP4K2NQO2KDM4E | |
| SCHEMBL2717077 | 0.81 | CYP1A2 (0.56) | CYP1A2KDM4ERAB9ALMNAPOLB | |
| SCHEMBL16431715 | 0.79 | CYP1A2 (0.46) | CYP1A2PDE10ANQO2KDM4EALDH1A1 | |
| SCHEMBL13737917 | 0.78 | CYP1A2 (0.48) | CYP1A2PDE10ANQO2KDM4ENPC1 | |
| SCHEMBL9186322 | 0.77 | CYP1A2 (0.52) | CYP1A2KDM4ERAB9ALMNAPOLB | |
| SCHEMBL16431788 | 0.76 | CYP1A2 (0.43) | CYP1A2PDE10AKDM4ELMNAPOLB | |
| SCHEMBL21645739 | 0.75 | CYP1A2 (0.46) | CYP1A2PDE10ANQO2KDM4ELMNA | |
| SCHEMBL13737717 | 0.75 | CYP1A2 (0.46) | CYP1A2PDE10ANQO2KDM4ELMNA | |
| SCHEMBL23797305 | 0.74 | CYP1A2 (0.48) | CYP1A2KDM4ERAB9ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588455-B1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2018-04-04 | — | — | EP | disclosed |
| EP-2588455-B1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9296758-B2 | 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296758-B2 | 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296758-B2 | 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| EP-2588455-A1 | 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012003498-A1 | 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003498-A1 | 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | NFATC1, ACIN1, ARF1 | CYP1A2 1018/4885PGK1 939/4885GSK3B 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.